IQIRVO® late-breaking data raises ambitions in PBC with more than 85% of patients on treatment achieving ALP normalization

PARIS, FRANCE, 5 NOVEMBER 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today late-breaking data from the ELSPIRE Phase III study in people living with primary biliary cholangitis (PBC) and alkaline phosphatase (ALP) levels between 1- 1.67× upper limit of normal (ULN). At Week 52, 85.3% of patients receiving IQIRVO® achieved normalization of ALP, a biochemical measure of disease activity, compared with 23.3% receiving placebo (p<0.0001). The findings will be presented as late-breaking data at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 and simultaneously published in HEPATOLOGY1. In addition, these data with an expanded patient population, are being shared with regulatory authorities.